Cantor Fitzgerald Maintains Overweight on NVIDIA, $200 Price Target

January 27, 2025 Analyst: C.J. Muse 1 min read Reproduced verbatim
Rating
Buy
Unchanged
Target
$200
Outcome
Reached
on October 28, 2025
Cantor and NVIDIA logos

What the analyst said

Cantor Fitzgerald analyst C.J. Muse reiterated an Overweight rating and $200 price target on NVIDIA (NASDAQ: NVDA).

“At the end of the day, DeepSeek’s advances mean we are closer to AGI.

Work will continue on pre-training, post-training, and time-based inference/reasoning, and future investments in large-scale clusters will only accelerate. All of which is bullish for AI.

Innovation is driving down cost of adoption and making AI ubiquitous – supporting Jevons Paradox. We see this progress as positive in the need for more and more compute over time (not less).”

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Where the price stands

NVDA trades at $214. The 27 analysts who set a target in the last 3 months range from $270 to $515, with a median of $315. This $200 target is 37% below the median, the lowest on the Street.

Since the note NVDA has moved +50% (from $143). The 12-month window closed on January 27, 2026.

Track record

This call✓ Target reached on October 28, 2025, 9 months after the note.

Firm track recordCantor: 86% of its 28 targets at least a year old were reached within 12 months (#12 of 28 firms); on NVIDIA, 3 of 5. Accuracy ranking →

Cantor on NVIDIA

Share
Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.